Compare AU
Compare CURE vs. BBUS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US Biotech (CURE) and the BetaShares Us Eqy Strong Bear - Ch (Hedge Fund) (BBUS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | BBUS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 16 |
Median incremental investment | $624.65 | $5,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,358.07 | $2,802.45 |
Average age group | > 35 | > 35 |
Key Summary
CURE | BBUS | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | BBUS.AX was created on 2015-08-24 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to help investors profit from, or protect against, a declining U.S. share market. It seeks to generate magnified returns that are negatively correlated to the returns of the U.S. share market (as measured by the S&P 500 index), hedged to Australian dollars. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | S&P500 EMINI FUT MAR25 (0 %) AUD - AUSTRALIA DOLLAR (113.35 %) USD - UNITED STATES DOLLAR (-13.35 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (73.66 %) Communication Services (26.34 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 1.38 % |
Key Summary
CURE | BBUS | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 1.38 % |
Price | $46.83 | $5.02 |
Size | $32.944 million | $148.606 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 1.89 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 26/08/2015 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | BBUS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 16 |
Median incremental investment | $624.65 | $5,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,358.07 | $2,802.45 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | BBUS | |
|---|---|---|
Pros |
| |
Cons |
|
CURE | BBUS |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |